BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27346339)

  • 41. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.
    D'Angelillo RM; Sciuto R; Ramella S; Papalia R; Jereczek-Fossa BA; Trodella LE; Fiore M; Gallucci M; Maini CL; Trodella L
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):296-302. PubMed ID: 25084612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
    Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
    Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using
    Nehra A; Parker WP; Haloi R; Park SS; Mynderse LA; Lowe VJ; Davis BJ; Quevedo JF; Johnson GB; Kwon ED; Karnes RJ
    J Urol; 2018 Mar; 199(3):726-733. PubMed ID: 28916273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
    Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
    Wachter S; Tomek S; Kurtaran A; Wachter-Gerstner N; Djavan B; Becherer A; Mitterhauser M; Dobrozemsky G; Li S; Pötter R; Dudczak R; Kletter K
    J Clin Oncol; 2006 Jun; 24(16):2513-9. PubMed ID: 16636343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.
    Rischke HC; Eiberger AK; Volegova-Neher N; Henne K; Krauss T; Grosu AL; Jilg CA
    Adv Med Sci; 2016 Sep; 61(2):212-218. PubMed ID: 26895459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective Evaluation of PSMA-Targeted
    Rowe SP; Campbell SP; Mana-Ay M; Szabo Z; Allaf ME; Pienta KJ; Pomper MG; Ross AE; Gorin MA
    J Nucl Med; 2020 Jan; 61(1):58-61. PubMed ID: 31201249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hybrid magnetic resonance and PET imaging for prostate cancer recurrence.
    Rednam N; Kundra V
    Curr Opin Oncol; 2023 May; 35(3):231-238. PubMed ID: 36966496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of
    Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
    Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
    Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
    Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
    Sung J; Espiritu JI; Segall GM; Terris MK
    BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
    Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
    Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.